At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.

At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."

More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.

About 9% of adults hospitalized with RSV died in the hospital or within 30 days of discharge, according to preliminary data presented at IDWeek 2026.

Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.

Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.

Posters in an artificial intelligence and digital care session at Kidney Week 2026 spanned CKD risk prediction and LLM-drafted prior authorization letters.

Financial toxicity affects nearly half of adults with sarcoma in a US cohort, and the authors call for routine screening to guide targeted support.